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Webappendix: Statistical Methods 
Data to December 2008 were organised into 4-weekly intervals (n=167475, excluding follow-up after 
randomisation to structured treatment interruptions in a sub-study), corresponding to the nurse visit 
schedule. Baseline factors were those at cART initiation. Time-dependent variables were the most 
recent values at/or prior to the start of each interval, allowing laboratory measurements within the first 
7 days of the interval only (3236 (1.9%) intervals for current CD4, other laboratory measures such as 
haemoglobin similar (data not shown)), likely corresponding to late clinic visits. Missing values were 
imputed by carrying the most recent observation forward (current CD4 >12 weeks before the start of an 
interval for 3135 (1.9%) of intervals and >24 weeks for 669 (0.4%) of intervals, other laboratory 
measures similar (data not shown)). 
 
Use of cotrimoxazole for prophylaxis within an interval was defined as at least 7 days use: in 96989 of 
97878 (99.1%) intervals it was used for the complete interval. Short (isolated) cotrimoxazole 
prescriptions for acute events were considered not to be prophylaxis (30 person-years, 0.2% follow-up) 
since participants being treated for such events were, by definition, already sick and at increased risk of 
clinical outcomes. Since inaccurate prescription dates could lead to cotrimoxazole prophylaxis initiated 
following a WHO stage 3/4 event being analysed as use prior to the event, we undertook sensitivity 
analyses shifting all periods of cotrimoxazole prophylaxis forward by 4 weeks.  
 
Pooled logistic regression models were used to approximate marginal structural Cox models, 
controlling for time-dependent confounders, using weights based on the inverse probability of a 
participant’s cotrimoxazole prophylaxis use, conditional on prognostic factors (inverse probability 
treatment weights, IPTW)1,2,3. The probability of cotrimoxazole prophylaxis use was modelled to 
obtain IPTW (treatment model). Then, the association between cotrimoxazole prophylaxis and outcome 
was estimated in a regression model including baseline variables and time-dependent cotrimoxazole 
prophylaxis, weighted using IPTW (outcome model).    
 
Baseline factors in treatment and outcome models were randomisation year, age, sex, CD4, 
haemoglobin, BMI, WHO HIV disease stage, first-line cART regimen and WHO stage 3/4 event in the 
4 weeks prior to randomisation. Time since randomisation was adjusted for using natural cubic splines 
with knots at 12, 48, 96, 144 and 192 weeks.  
 
The probability of cotrimoxazole prophylaxis use in each four week interval, A(k) where A(k)=1 
indicates use of prophylaxis for at least 7 days in interval k, was estimated using pooled logistic 
regression models for each centre (n=4, satellite clinic a separate centre) and randomised monitoring 
group, as follows:  
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 where α0(k) is an interval specific intercept (modelled by cubic splines), )1( −kA  is cotrimoxazole 
history up to and including interval k-1, V includes baseline factors described above, )(kL  is history 
of time-dependent confounders up to interval k. History of cotrimoxazole use was restricted to use on 
cART, assuming that any residual benefit of use prior to cART on outcomes could be explained by 
baseline covariates. Cotrimoxazole use in the preceding 6 intervals (24 weeks) predicted current use 
after 24 weeks on cART, so we fitted separate models for weeks 12-24 and >24 weeks on cART, 
including cotrimoxazole prophylaxis in the previous 3 (k-1,…,k-3) and 6 intervals (k-1, …,k-6) 
respectively as predictors in our treatment models. Time-dependent variables included in )(kL were 
current CD4 and haemoglobin (most recent prior to interval k or in the first 7 days of interval k) and 
BMI (most recent prior to interval k), a WHO stage 3/4 event in the previous 4 weeks (interval k-1), an 
earlier WHO stage 3/4 event since randomisation (in interval k-2,…,1) and randomisation in the STI 
study (never, to CT) prior to interval k, including interactions between these time-dependent variables 
and cotrimoxazole prophylaxis (on/off) in the previous four week period (interval k-1). To estimate the 
effects of cotrimoxazole on neutrophils (or platelets), baseline and time-dependent neutrophils 
(platelets) were also included in the treatment model. All factors were checked for positivity and CD4 
count was grouped (<50, 50-100, 100-200, 200-350, >350) after 24 weeks on cART as small numbers 
of participants started cotrimoxazole prophylaxis at high CD4 counts4. Sensitivity analyses additionally 
included last-but-one CD4, haemoglobin (usually 12 weeks prior to current value) and BMI (4 weeks 
prior to current value) and interactions with calendar period (results similar). Baseline covariates were 
assumed to explain cotrimoxazole prophylaxis for the first 12 weeks on cART because there were too 
few cotrimoxazole changes during the first 12 weeks to model treatment (in total 121 participants 
started and 12 participants stopped cotrimoxazole prophylaxis), so IPTW weights were fixed as 1 in 
this period. 
 
To adjust for potential selection bias from loss to follow-up, censoring weights were also estimated1. 
For non-fatal outcomes, censoring from death and from loss to follow-up (or end of follow-up in 
December 2008) were treated as separate outcomes in multinomial logistic regression models. 
Treatment and censoring weights were stabilised as standard and the time-dependent product used to 
weight outcome models, thus weighted regressions estimate the effect of an individual’s complete 
cotrimoxazole history since starting cART on outcomes1. We explored the distribution and effect of our 
stabilised weights by progressive truncation4; in presented models weights were truncated at the 1st and 
99th percentiles by centre and randomised monitoring group (in our primary mortality model the overall 
mean weight was 1.00, minimum 0.04, maximum 8.1; weights had means very close to 1 within centre, 
monitoring group and by time on cART (≤72 weeks, >72 weeks)). Confidence intervals for treatment 
effects are based on robust variance estimates1, confirmed by bootstrapping in main outcome analyses.  
 
Outcome models adjusted for baseline pre-cART factors (as above), centre and randomised monitoring 
group. Twelve-weekly repeated measures were used for continuous outcomes. Models restricted to 
outcomes post-12 weeks on cART additionally adjusted for time-dependent variables at 12 weeks and 
cotrimoxazole prophylaxis use during the first 12 weeks on cART. Heterogeneity across subgroups was 
assessed using interaction tests. 
 
We excluded Harare participants from analyses of malaria because of low rates of disease. We used 
history-adjusted marginal structural models5 to incorporate more than one malaria event per participant. 
Time was measured from trial entry or 28 days after the previous malaria episode (baseline), and 
outcome regression models adjusted for time-dependent variables including previous malaria episode 
and history of cotrimoxazole prophylaxis at this baseline.  
 
We investigated whether the effect of cotrimoxazole prophylaxis differed according to time since 
cART initiation by fitting interaction terms between current cotrimoxazole use and time on cART 
modelled using natural cubic splines, representing statistically significant non-linearity using piecewise 
linear effects and categorisation6. We investigated whether the effect of cotrimoxazole prophylaxis 
differed by current CD4 using history-adjusted marginal structural models, treating each 12-weekly 
follow-up visit as a new baseline and considering mortality over the following 12 weeks5. Time-
dependent variables (including current CD4), history of cotrimoxazole prophylaxis and time on cART 
up to each baseline visit were included as predictors within the outcome regression model with time-
dependent variables after baseline adjusted for using IPTW. Results were similar for 48 week follow-
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